Is the Prognostic Significance of O6-methylguanine- DNA Methyltransferase Promoter Methylation Equally Important in Glioblastomas of Patients from Different Continents? A Systematic Review with Meta-analysis

Overview

Journal Cancer Manag Res

Publisher Dove Medical Press

Specialty Oncology

Date 2017 Oct 17

PMID 29033608

Citations 10

Authors

Wei Meng

Yangyang Jiang

Jie Ma

Affiliations

Soon will be listed here.

Abstract

Background: O6-methylguanine-DNA methyltransferase (MGMT) is an independent predictor of therapeutic response and potential prognosis in patients with glioblastoma multiforme (GBM). However, its significance of clinical prognosis in different continents still needs to be explored.

Patients And Methods: To explore the effects of MGMT promoter methylation on both progression-free survival (PFS) and overall survival (OS) among GBM patients from different continents, a systematic review of published studies was conducted.

Results: A total of 5103 patients from 53 studies were involved in the systematic review and the total percentage of MGMT promoter methylation was 45.53%. Of these studies, 16 studies performed univariate analyses and 17 performed multivariate analyses of MGMT promoter methylation on PFS. The pooled hazard ratio (HR) estimated for PFS was 0.55 (95% CI 0.50, 0.60) by univariate analysis and 0.43 (95% CI 0.38, 0.48) by multivariate analysis. The effect of MGMT promoter methylation on OS was explored in 30 studies by univariate analysis and in 30 studies by multivariate analysis. The combined HR was 0.48 (95% CI 0.44, 0.52) and 0.42 (95% CI 0.38, 0.45), respectively.

Conclusion: In each subgroup divided by areas, the prognostic significance still remained highly significant. The proportion of methylation in each group was in inverse proportion to the corresponding HR in the univariate and multivariate analyses of PFS. However, from the perspective of OS, compared with data from Europe and the US, higher methylation rates in Asia did not bring better returns.

Citing Articles

Polyphenols as Wnt/β-catenin pathway modulators: A promising strategy in clinical neurodegeneration.

Utpal B, Roy S, Zehravi M, Sweilam S, Raja A, Akiful Haque M Animal Model Exp Med. 2025; 8(2):266-286.

PMID: 39808166 PMC: 11871115. DOI: 10.1002/ame2.12525.

Advances in Glioblastoma Therapy: An Update on Current Approaches.

Angom R, Nakka N, Bhattacharya S Brain Sci. 2023; 13(11).

PMID: 38002496 PMC: 10669378. DOI: 10.3390/brainsci13111536.

The Significance of Promoter Methylation Status in Diffuse Glioma.

Jovanovic N, Lazarevic M, Cvetkovic V, Nikolov V, Kostic Peric J, Ugrin M Int J Mol Sci. 2022; 23(21).

PMID: 36361838 PMC: 9654114. DOI: 10.3390/ijms232113034.

Molecular and Circulating Biomarkers in Patients with Glioblastoma.

Senhaji N, Squalli Houssaini A, Lamrabet S, Louati S, Bennis S Int J Mol Sci. 2022; 23(13).

PMID: 35806478 PMC: 9267689. DOI: 10.3390/ijms23137474.

Prognostic and Predictive Biomarkers in Gliomas.

Sledzinska P, Bebyn M, Furtak J, Kowalewski J, Lewandowska M Int J Mol Sci. 2021; 22(19).

PMID: 34638714 PMC: 8508830. DOI: 10.3390/ijms221910373.

References

Etcheverry A, Aubry M, de Tayrac M, Vauleon E, Boniface R, Guenot F . DNA methylation in glioblastoma: impact on gene expression and clinical outcome. BMC Genomics. 2010; 11:701. PMC: 3018478. DOI: 10.1186/1471-2164-11-701. View

Stupp R, Hegi M, Mason W, van den Bent M, Taphoorn M, Janzer R . Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009; 10(5):459-66. DOI: 10.1016/S1470-2045(09)70025-7. View

Friedman H, McLendon R, Kerby T, Dugan M, Bigner S, HENRY A . DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma. J Clin Oncol. 1998; 16(12):3851-7. DOI: 10.1200/JCO.1998.16.12.3851. View

Ellingson B, Cloughesy T, Pope W, Zaw T, Phillips H, Lalezari S . Anatomic localization of O6-methylguanine DNA methyltransferase (MGMT) promoter methylated and unmethylated tumors: a radiographic study in 358 de novo human glioblastomas. Neuroimage. 2011; 59(2):908-16. DOI: 10.1016/j.neuroimage.2011.09.076. View

Weller M, Felsberg J, Hartmann C, Berger H, Steinbach J, Schramm J . Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. J Clin Oncol. 2009; 27(34):5743-50. DOI: 10.1200/JCO.2009.23.0805. View

Tierney J, Stewart L, Ghersi D, Burdett S, Sydes M . Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007; 8:16. PMC: 1920534. DOI: 10.1186/1745-6215-8-16. View

Brell M, Tortosa A, Verger E, Gil J, Vinolas N, Villa S . Prognostic significance of O6-methylguanine-DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression in anaplastic gliomas. Clin Cancer Res. 2005; 11(14):5167-74. DOI: 10.1158/1078-0432.CCR-05-0230. View

Skiriute D, Vaitkiene P, Saferis V, Asmoniene V, Skauminas K, Deltuva V . MGMT, GATA6, CD81, DR4, and CASP8 gene promoter methylation in glioblastoma. BMC Cancer. 2012; 12:218. PMC: 3404983. DOI: 10.1186/1471-2407-12-218. View

Hegi M, Liu L, Herman J, Stupp R, Wick W, Weller M . Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol. 2008; 26(25):4189-99. DOI: 10.1200/JCO.2007.11.5964. View

10.

Higgins J, Thompson S . Quantifying heterogeneity in a meta-analysis. Stat Med. 2002; 21(11):1539-58. DOI: 10.1002/sim.1186. View

11.

Stupp R, Hegi M, Gorlia T, Erridge S, Perry J, Hong Y . Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2014; 15(10):1100-8. DOI: 10.1016/S1470-2045(14)70379-1. View

12.

Verbeek B, Southgate T, Gilham D, Margison G . O6-Methylguanine-DNA methyltransferase inactivation and chemotherapy. Br Med Bull. 2008; 85:17-33. DOI: 10.1093/bmb/ldm036. View

13.

Fiano V, Trevisan M, Trevisan E, Senetta R, Castiglione A, Sacerdote C . MGMT promoter methylation in plasma of glioma patients receiving temozolomide. J Neurooncol. 2014; 117(2):347-57. DOI: 10.1007/s11060-014-1395-4. View

14.

Park C, Park S, Lee S, Kim C, Kim D, Paek S . Methylation status of the MGMT gene promoter fails to predict the clinical outcome of glioblastoma patients treated with ACNU plus cisplatin. Neuropathology. 2009; 29(4):443-9. DOI: 10.1111/j.1440-1789.2008.00998.x. View

15.

Villani V, Casini B, Pace A, Prosperini L, Carapella C, Vidiri A . The Prognostic Value of Pyrosequencing-Detected MGMT Promoter Hypermethylation in Newly Diagnosed Patients with Glioblastoma. Dis Markers. 2015; 2015:604719. PMC: 4548097. DOI: 10.1155/2015/604719. View

16.

Begg C, Mazumdar M . Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994; 50(4):1088-101. View

17.

Gerstner E, Duda D, Tomaso E, Ryg P, Loeffler J, Sorensen A . VEGF inhibitors in the treatment of cerebral edema in patients with brain cancer. Nat Rev Clin Oncol. 2009; 6(4):229-36. PMC: 4793889. DOI: 10.1038/nrclinonc.2009.14. View

18.

Lechapt-Zalcman E, Levallet G, Dugue A, Vital A, Diebold M, Menei P . O(6) -methylguanine-DNA methyltransferase (MGMT) promoter methylation and low MGMT-encoded protein expression as prognostic markers in glioblastoma patients treated with biodegradable carmustine wafer implants after initial surgery followed by.... Cancer. 2012; 118(18):4545-54. DOI: 10.1002/cncr.27441. View

19.

Tang K, Jin Q, Yan W, Zhang W, You G, Liu Y . Clinical correlation of MGMT protein expression and promoter methylation in Chinese glioblastoma patients. Med Oncol. 2011; 29(2):1292-6. DOI: 10.1007/s12032-011-9901-4. View

20.

Weller M, Stupp R, Reifenberger G, Brandes A, van den Bent M, Wick W . MGMT promoter methylation in malignant gliomas: ready for personalized medicine?. Nat Rev Neurol. 2009; 6(1):39-51. DOI: 10.1038/nrneurol.2009.197. View